Letters
Human papillomavirus vaccination
Glimpse into the black box of human papillomavirus vaccination
BMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a1046 (Published 28 July 2008) Cite this as: BMJ 2008;337:a1046
- Peter M English, consultant in public health medicine1,
- Keith Neal, professor, epidemiology of infectious diseases, epidemiology and public health 2
- 1Surrey KT19 9XF
- 2University of Nottingham, NG7 2RH
- petermbenglish{at}gmail.com
We welcome an opportunity to get a glimpse into the black box underlying the recent decisions about human papillomavirus (HPV) vaccination.1 We would like to reflect on the assumptions made. GlaxoSmithKline claims that Cervarix will provide protection longer, which would favour Cervarix. The paper by Jit et al does not reflect this (which is probably appropriate, since these claims are disputed).
The paper’s assumption that those …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £138 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (plus VAT)
You can download a PDF version for your personal record.